Johnson & Johnson (JNJ) Earnings History
Annual and quarterly earnings data from 1989 to 2024
Loading earnings history...
EPS Growth Rates (CAGR)
Compound annual growth rate of diluted earnings per share
CAGR (Compound Annual Growth Rate) shows the annualized growth rate of EPS over the specified period. A higher CAGR indicates stronger earnings momentum.
Profitability Analysis
Margin trends over time
| Year | Gross Margin | Operating Margin | Net Margin |
|---|---|---|---|
| 2024 | 69.1% | 24.9% | 15.8% |
| 2023 | 68.8% | 27.5% | 41.3% |
| 2022 | 69.3% | 26.3% | 22.4% |
| 2021 | 70.3% | 26.6% | 26.5% |
| 2020 | 65.6% | 23.9% | 17.8% |
Download Data
Export JNJ earnings history in CSV or JSON format
Free sign-in required to download data
Johnson & Johnson (JNJ) Earnings Overview
As of February 28, 2026, Johnson & Johnson (JNJ) reported trailing twelve-month net income of $25.12B, reflecting -0.6% year-over-year growth. The company earned $10.34 per diluted share over the past four quarters, with a net profit margin of 0.2%.
Looking at the long-term picture, JNJ's 5-year EPS compound annual growth rate (CAGR) stands at +0.6%, reflecting modest earnings expansion. The company achieved its highest annual net income of $35.15B in fiscal 2023.
Johnson & Johnson maintains positive profitability with a gross margin of 0.7%, operating margin of 0.2%, and net margin of 0.2%. The company continues to generate positive earnings from operations. View revenue history →
Compared to industry peers including LLY ($18.41B net income, 0.2% margin), AZN ($10.22B net income, 0.2% margin), BMY ($6.04B net income, -0.2% margin), JNJ has room to improve margins relative to the peer group. Compare JNJ vs LLY →
Peer Comparison
Earnings metrics vs industry competitors
Historical Data
36 years| Fiscal Year | Net Income | YoY % | Operating Income | EPS (Diluted) | Net Margin | Op. Margin |
|---|---|---|---|---|---|---|
| 2024 | $14.07B | -60.0% | $22.15B | $5.79 | 15.8% | 24.9% |
| 2023 | $35.15B | +95.9% | $23.41B | $13.72 | 41.3% | 27.5% |
| 2022 | $17.94B | -14.1% | $21.01B | $6.73 | 22.4% | 26.3% |
| 2021 | $20.88B | +41.9% | $20.94B | $7.81 | 26.5% | 26.6% |
| 2020 | $14.71B | -2.7% | $19.73B | $5.51 | 17.8% | 23.9% |
| 2019 | $15.12B | -1.2% | $20.97B | $5.63 | 18.4% | 25.6% |
| 2018 | $15.30B | +1076.7% | $21.18B | $5.61 | 18.8% | 26.0% |
| 2017 | $1.30B | -92.1% | $18.90B | $0.47 | 1.7% | 24.7% |
| 2016 | $16.54B | +7.3% | $20.89B | $5.93 | 23.0% | 29.1% |
| 2015 | $15.41B | -5.6% | $18.29B | $5.48 | 22.0% | 26.1% |
See JNJ's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs JNJ Undervalued?
See our Bear / Base / Bull DCF models and intrinsic value estimates.
View ValuationCompare JNJ vs AGIO
See how JNJ stacks up against sector leader Agios Pharmaceuticals, Inc..
Start ComparisonFrequently Asked Questions
Is JNJ growing earnings?
JNJ EPS of $10.34 reflects slowing growth at -0.6%, below the 5-year CAGR of +0.6%. TTM net income is $25.1B. Expansion rate has moderated.
What are JNJ's profit margins?
Johnson & Johnson net margin is +0.2%, with operating margin at +0.2%. Below-average margins reflect competitive or cost pressures.
How consistent are JNJ's earnings?
JNJ earnings data spans 1989-2024. The current earnings trend is -0.6% YoY. Historical data enables comparison across business cycles.